Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 4NIH 4NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Central Nervous System Neoplasms 1

Interventions

Specimen Handling 68Magnetic Resonance Spectroscopy 53Cyclophosphamide 45Vincristine 38Radiotherapy 31Radiation 31Cisplatin 31Carboplatin 30Dexamethasone 27Etoposide 26Doxorubicin 25Biopsy 25daratumumab 17Radiotherapy, Intensity-Modulated 17Prednisone 17Platinum 16Paclitaxel 16Irinotecan 16Cytarabine 16durvalumab 15Gemcitabine 151,2-diaminocyclohexaneplatinum II citrate 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 14Lenalidomide 13X-Rays 12Watchful Waiting 12Rituximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × larotrectinib × 1 year × Clear all
NCT03834961 2025-12-02

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Children's Oncology Group

Phase 2 Active not recruiting
33 enrolled 18 charts
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡